Insider Monkey
Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement
📈
AI Sentiment
Highly Positive
8/10
- Home
- ANNX
ANNX
Annexon Inc.
as of 12-04-2025 3:46pm EST
$4.53
+$0.25
+5.72%
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Chart Type:
Time Range:
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 334.1M | IPO Year: | 2020 |
| Target Price: | $16.60 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $5.66 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ANNX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 80.41%
80.41%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Annexon Inc. (ANNX)
Carson William H.
Buy
Director
ANNX Dec 1, 2025
Avg Cost/Share
$4.47
Shares
4,115
Total Value
$18,394.05
Owned After
50,290
SEC Form 4
Satter Muneer A
Buy
Director
ANNX Nov 19, 2025
Avg Cost/Share
$3.94
Shares
500,000
Total Value
$1,970,000.00
Owned After
8,906,024
SEC Form 4
Satter Muneer A
Buy
Director
ANNX Nov 18, 2025
Avg Cost/Share
$3.18
Shares
500,000
Total Value
$1,590,000.00
Owned After
8,906,024
SEC Form 4
Satter Muneer A
Buy
Director
ANNX Nov 17, 2025
Avg Cost/Share
$2.99
Shares
500,000
Total Value
$1,495,000.00
Owned After
8,906,024
SEC Form 4
Carson William H.
Buy
Director
ANNX Oct 30, 2025
Avg Cost/Share
$3.17
Shares
4,115
Total Value
$13,044.55
Owned After
50,290
SEC Form 4
Carson William H.
Buy
Director
ANNX Sep 30, 2025
Avg Cost/Share
$3.05
Shares
4,115
Total Value
$12,550.75
Owned After
50,290
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Carson William H. | ANNX | Director | Dec 1, 2025 | Buy | $4.47 | 4,115 | $18,394.05 | 50,290 | |
| Choi Jung | ANNX | Director | Dec 1, 2025 | Buy | $4.19 | 33,000 | $138,270.00 | 33,000 | |
| Satter Muneer A | ANNX | Director | Nov 19, 2025 | Buy | $3.94 | 500,000 | $1,970,000.00 | 8,906,024 | |
| Satter Muneer A | ANNX | Director | Nov 18, 2025 | Buy | $3.18 | 500,000 | $1,590,000.00 | 8,906,024 | |
| Satter Muneer A | ANNX | Director | Nov 17, 2025 | Buy | $2.99 | 500,000 | $1,495,000.00 | 8,906,024 | |
| Carson William H. | ANNX | Director | Oct 30, 2025 | Buy | $3.17 | 4,115 | $13,044.55 | 50,290 | |
| Carson William H. | ANNX | Director | Sep 30, 2025 | Buy | $3.05 | 4,115 | $12,550.75 | 50,290 |
Latest Annexon Inc. News
ANNX Breaking Stock News: Dive into ANNX Ticker-Specific Updates for Smart Investing
Compare ANNX vs Leading Stocks
See how ANNX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.